I am a
Home I AM A Search Login

Papers of the Week

Papers: 8 Jan 2022 - 14 Jan 2022

Human Studies

2022 Jan 11

Neurol Sci

Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data.


Guerzoni S, Baraldi C, Pensato U, Favoni V, Lo Castro F, Cainazzo M M, Cevoli S, Pani L
Neurol Sci. 2022 Jan 11.
PMID: 35015202.


Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor which has been found effective even for the treatment of chronic migraine (CM) complicated with medication overuse headache (MOH). According to the present guidelines, the treatment with erenumab should continue for up to 1 year. The aim of the present study is to explore the evolution of patients affected by CM and MOH at the baseline, after erenumab discontinuation.